Hopitaux Prives De Metz — Clinical Trial Site

39 Registered trials

15 Currently recruiting

Organisation

Hopitaux Prives De Metz

Location

Vantoux, France

Identifier

ORG-100043189

Address

Rue Du Pre Montois, 57070, France

Departments

2305:Pneumologie
Cancérologie-pneumologie
Chirurgie gynécologique & sénologique
Département de Pneumologie
Internal Medicine
Médecine interne
Medical Oncology
N/A
Oncologie
Oncologie Médicale
Oncology
Oncology Unit
Pneumologie
Pneumology
Pulmonology department
Réanimation
Service d'Oncologie
Service de Pneumologie
Service de Réanimation Polyvalente
Service Pneumologie

Clinical trials at this site (39)

Search interface

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending

2025-521331-36-00 Patient with stabilized SSc-ILD (as defined by a declin 10
Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Non Small Cell Lung Cancer 4
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial Pending

2025-524976-40-00 patients with influenza-induced acute hypoxemic respira 5
A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro… Recruiting

2025-522892-27-00 Bronchiectasis 4 2026-03-21
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a… Recruiting

2023-505172-29-00 Resectable Non-small Cell Lung Cancer 4 2025-04-24
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 PR3-ANCA granulomatosis with polyangiitis (Wegener’s) 4 2025-12-19
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and… Recruiting

2024-519052-82-00 pleural mesothelioma 4 2025-06-30
Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting

2024-516242-19-00 lupus nephritis 5 2024-11-05
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Advanced or Metastatic Non-squamous Non-Small Cell Lung 1 2024-10-08
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Participants with treatment-naïve metastatic squamous N 5 2024-09-02
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting

2023-509761-21-00 Metastatic colorectal cancer 5 2024-07-08
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting

2022-501057-36-00 ANCA-associated vasculitis 5 2023-10-24
EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co… Recruiting

2022-501335-16-00 Interstitial lung disease 10 2023-01-16
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting

2024-513427-17-00 Well controlled severe allergic asthma 6 2021-05-20
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended

2024-515538-34-00 Head and Neck Squamous Cell Carcinoma 10 2025-02-27
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
TocilizuMab discontinuAtion in GIant Cell Arteritis Ended

2023-505515-21-00 Giant Cell Arteritis 5 2024-04-02
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03